证券代码：300122 证券简称：智飞生物 公告编号：2025-40 重庆智飞生物制品股份有限公司 关于重组带状疱疹疫苗（CHO 细胞） 获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于近日获悉，由全资子 公司安徽智飞龙科马生物制药有限公司（以下简称"智飞龙科马"）研发的重组带 状疱疹疫苗（CHO 细胞）获得国家药品监督管理局药物临床试验批准通知书（通 知书编号：2025LP01740），同意在 40 岁及以上人群中开展用于预防带状疱疹的 临床试验。 一、研发项目简介 带状疱疹（herpes zoster）是由长期潜伏在脊髓后根神经节或颅神经节内的水 痘-带状疱疹病毒（varicella-zoster virus，VZV）经再激活引起的感染性皮肤病。 有数据表明，90%以上的成人体内都潜伏有水痘-带状疱疹病毒，大约 1/3 的人在 一生中会患带状疱疹。带状疱疹是皮肤科常见病，除皮肤损害外，常伴有神经病 理性疼痛，多见于年龄较大、免疫抑制或免疫缺陷等人群，严重影响患者生活质 量。带状 ...

Core Viewpoint - Zhifei Biological plans to issue up to 6 billion yuan in corporate bonds to support investments in technological innovation, replace interest-bearing liabilities, and replenish working capital [1] Group 1: Financial Performance - In 2024, Zhifei Biological reported a significant decline in performance, with total revenue of 26.07 billion yuan, a year-on-year decrease of 50.7%, and a net profit attributable to shareholders of 2.02 billion yuan, down 75.0% [1] - The revenue from agency products, which has historically contributed over 70% to the company's performance, saw a drastic reduction, leading to the overall decline in revenue [1][2] - The company's cash flow turned negative in 2024, with an operating cash flow of -4.414 billion yuan, a decline of 149.6% compared to the previous year [3] Group 2: Product Performance - Revenue from Zhifei Biological's self-developed products increased by 14.9% to 1.18 billion yuan, while revenue from agency products fell by 52.5% to 24.67 billion yuan [2] - The core product, the HPV vaccine, experienced a significant drop in sales, with the issuance of four-valent HPV vaccines down by 95.5% and nine-valent HPV vaccines down by 14.8% [2] Group 3: Strategic Initiatives - The company aims to focus on "de-stocking, collecting payments, and reducing liabilities" as its core strategy for 2025 to mitigate operational risks [3] - The issuance of 6 billion yuan in corporate bonds is seen as a crucial step in reducing liabilities and addressing financial risks [3]

Core Viewpoint - The A-share market in the first half of the year saw significant fluctuations in the biopharmaceutical sector, with over 65% of the 479 listed stocks outperforming the market, while some stocks experienced substantial declines without performance support [1][3]. Group 1: Stock Performance - Among the biopharmaceutical stocks, 313 outperformed the market, with Shuyatain (300204) achieving a remarkable increase of over 403.1%, making it the "king of growth" [1][3]. - Conversely, Zhifei Biological experienced the largest decline, with a cumulative drop of 25.51% in stock price [7][8]. - A total of 13 stocks saw their prices double, including Shuyatain, Saifen Technology, and Chaoyan Co., with increases of 297.72% and 277.47% respectively [3][4]. Group 2: Financial Performance - Shuyatain's stock surge is attributed to the progress of several innovative drugs, including the acceptance of its application for a new drug by the National Medical Products Administration [3][4]. - Zhifei Biological's financials indicate a significant decline, with a projected revenue of 26.07 billion yuan in 2024, down 50.74%, and a net profit drop of 74.99% [8][12]. - Some stocks with significant price increases, such as Yipin Hong, reported a revenue decline of 42.07% and a net loss of 540 million yuan in 2024 [12][13]. Group 3: Market Trends - The biopharmaceutical sector is facing challenges, including market competition and changing consumer demand, which have pressured companies to adjust their strategies [10][11]. - The recent performance of innovative drug companies reflects a transition from loss-making to profitability, attracting investor interest [4][10]. - Despite some stocks showing strong price increases, many lack corresponding financial performance, indicating a potential disconnect between market sentiment and fundamentals [12][13].

证券代码：300122 证券简称：智飞生物 公告编号：2025-39 | 发明专利名称 | 专利号 | 专利证书号 | 专利类型 | 专利申请日 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | --- | | 一种引物对及其 在 BCG-CpG-DNA | ZL202211426011.7 | 第 8029182 号 | 发明专利 | 2022 年 11 月 | 2025 年 06 月 | 智飞生物 智飞绿竹 | | 佐剂质控方法中 | | | | 14 日 | 27 日 | | | | | | | | | 智飞龙科马 | | 的应用 | | | | | | | 上述发明专利是在公司自主研发且尚处于在研阶段的冻干重组结核疫苗 （AEC/BC02）的研发过程中申请获得，将在公司相关在研产品上应用。该专利证 书的取得不会对公司近期生产经营产生重大影响，但有利于进一步完善公司知识 产权保护体系，充分发挥自主知识产权优势，促进技术创新，提升公司的核心竞 争力。 特此公告 重庆智飞生物制品股份有限公司董事会 2025 年 7 月 1 日 1 重庆智飞生物制品 ...

Core Viewpoint - The company, Zhifei Biological Products (300122.SZ), is facing significant financial pressure and is attempting to alleviate this through a bond issuance of up to 6 billion yuan to optimize its debt structure and meet operational funding needs [1][5][15]. Financial Performance - As of the end of Q1 2024, the company's short-term debt was approximately 148 billion yuan, which is 4.8 times its cash reserves of 30.69 billion yuan [6][10]. - The company reported a 50% decline in revenue and a 75% drop in net profit attributable to shareholders for 2024, marking its first loss since 2010 [1][19]. - Financial expenses surged by 1011.22% year-on-year to 66.27 million yuan in Q1 2024, indicating a rapid deterioration in financial health [7][8]. - The operating cash flow turned negative for the first time in 2024, with a loss of 4.414 billion yuan, a 149.6% decline compared to the previous year [8][10]. Market Performance - The company's stock has seen a decline of over 80% over the past four years, with a peak price of 231.19 yuan per share in May 2021, dropping to 19.35 yuan per share by June 2023 [2][12]. - The market capitalization has decreased from 369.9 billion yuan at its peak to approximately 46.3 billion yuan, reflecting a significant loss in shareholder wealth [12]. Product and Sales Challenges - The company has experienced a severe decline in product sales, particularly in its agency model for Merck's HPV vaccines, leading to inventory levels reaching 219 billion yuan in Q1 2024 [20][21]. - Sales of key products, including the four-valent and nine-valent HPV vaccines, have plummeted, with some products seeing a drop in batch issuance of up to 95.49% [19][21]. - Despite the revenue decline, sales expenses remained relatively stable at 2.651 billion yuan, indicating ongoing marketing efforts [21]. Strategic Response - In response to financial pressures, the company is focusing on self-developed products, with R&D investments increasing from 1.113 billion yuan in 2022 to 1.391 billion yuan in 2024 [22]. - The company has established nine technology R&D platforms and has 34 self-developed projects, with 19 in clinical trials or registration stages [22].

证券代码：300122 证券简称：智飞生物 公告编号：2025-38 重庆智飞生物制品股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）及全资子公司——北 京智飞绿竹生物制药有限公司（以下简称"智飞绿竹"）、安徽智飞龙科马生物 制药有限公司（以下简称"智飞龙科马"）于近日取得中华人民共和国国家知识 产权局颁发的发明专利证书。具体情况如下： | 发明专利名称 | 专利号 | 专利证书号 | 专利类型 | 专利申请日 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | --- | | 一种肺炎球菌结 | | | | 2024 年 01 月 | 2025 年 06 月 | 智飞生物 | | 合物组合疫苗及 | ZL202410094851.0 | 第 8027249 号 | 发明专利 | 24 日 | 24 日 | 智飞绿竹 | | 其制备方法 | | | | | | 智飞龙科马 | | 一种用于呼吸道 | | | | 2 ...

Core Viewpoint - The document outlines the management and usage system for funds raised through bond issuance by Chongqing Zhifei Biological Products Co., Ltd, emphasizing the protection of investors' rights and the efficient use of raised funds [2][4]. Group 1: General Principles - The system is established to regulate the management and use of funds raised through bond issuance, ensuring compliance with relevant laws and regulations [2]. - The term "raised funds" refers to the capital collected from investors through public or private bond issuance [2]. Group 2: Fund Management and Storage - The company must open a special account for the raised funds, ensuring that these funds are managed separately and not mixed with other funds [4][6]. - The company is required to sign a tripartite supervision agreement with the entrusted management institution and the supervising bank before the funds arrive in the special account [4][6]. Group 3: Fund Usage - The company must strictly adhere to the financial management system and the established procedures when using the raised funds [7][8]. - The use of raised funds for non-productive expenditures or to cover losses is prohibited [8]. Group 4: Monitoring and Reporting - The company must continuously monitor the actual management and usage of the raised funds and disclose this information accurately in periodic reports [8][9]. - Any changes to the planned use of raised funds must be approved by the board of directors and disclosed to the entrusted management and bondholders [9]. Group 5: Accountability - Violations of the established system by the company or its executives may result in disciplinary actions, including potential legal consequences [9].

Core Viewpoint - The document outlines the information disclosure management system for Chongqing Zhifei Biological Products Co., Ltd., emphasizing the importance of timely, accurate, and comprehensive disclosure of bond-related information to protect investors' rights and comply with regulatory requirements [1][2][3]. Group 1: General Provisions - The system is established to regulate the disclosure of bond information, ensuring compliance with relevant laws and regulations [1]. - The company must disclose information that may significantly impact its debt repayment ability or investors' rights [1][2]. - Information must be based on objective facts and should not contain false statements or misleading content [2][3]. Group 2: Disclosure Content and Standards - Required disclosures include issuance and fundraising information, periodic reports, and temporary reports [7]. - Negative events must be disclosed with a comprehensive analysis of their impact on debt repayment ability and the measures taken in response [3][4]. - The company can voluntarily disclose additional relevant information, ensuring it does not conflict with legally required disclosures [3][4]. Group 3: Disclosure Procedures - The company must follow specific procedures for disclosing periodic and temporary reports, involving various management levels for review and approval [17][18]. - Timely disclosure of significant events is required within two trading days of becoming aware of such events [5][6]. Group 4: Responsibilities and Management - The board of directors is responsible for overseeing information disclosure, with the chairman as the primary responsible person [21][22]. - The board secretary coordinates disclosure activities and ensures compliance with legal and regulatory requirements [22][23]. - The audit committee monitors the information disclosure practices of the company's directors and senior management [13]. Group 5: Subsidiary Disclosure Management - Subsidiaries must appoint personnel responsible for information disclosure and report relevant information to the parent company [29][30]. - Significant events at subsidiaries that may affect the company's financial status must be reported in accordance with the established system [30][31]. Group 6: Implementation and Amendments - The system becomes effective upon approval by the board of directors and is subject to amendments as necessary [32][33]. - Any matters not covered by the system will follow applicable laws, regulations, and the company's internal management rules [32][33].

Core Viewpoint - Chongqing Zhifei Biological Products Co., Ltd. plans to issue corporate bonds to raise funds for technological innovation, debt restructuring, and working capital needs, with a total issuance scale not exceeding RMB 6 billion [1][2]. Group 1: Issuance Overview - The proposed bond issuance scale is up to RMB 60 billion, with the specific amount to be determined based on the company's funding needs and market conditions [2]. - The bonds will be issued through a book-building method, which may involve either a single issuance or multiple issuances [2]. - The face value of the bonds will be RMB 100, issued at par [2]. - The bonds will be offered to qualified professional investors, without preferential allocation to existing shareholders [2]. - The issuance will occur at an opportune time based on actual funding needs, on the Shenzhen Stock Exchange [2]. - The bond term will not exceed 10 years, including both public and private placements [2]. Group 2: Fund Utilization and Terms - The funds raised will be used for investments in technological innovation, debt replacement, and working capital, with specific allocations to be determined by the board [2][3]. - The bonds will have a fixed interest rate, determined through a pricing inquiry process, with interest paid annually and principal repaid at maturity [3]. - The bonds will be issued without collateral [4]. - The underwriting will be conducted through a firm commitment basis, with plans for listing on the Shenzhen Stock Exchange post-issuance [4]. Group 3: Authorization and Approval Process - The board seeks authorization from the shareholders' meeting to manage all aspects of the bond issuance, including terms and conditions [5][6]. - The issuance has been approved by the board and supervisory committee but requires shareholder approval and regulatory clearance before proceeding [6].

证券代码：300122 证券简称：智飞生物 公告编号：2025-36 重庆智飞生物制品股份有限公司 关于发行公司债券预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆智飞生物制品股份有限公司（以下简称"公司"）于 2025 年 6 月 26 日 召开了第六届董事会第六次会议、第六届监事会第五次会议，审议通过了《关于 发行公司债券的议案》《关于提请股东大会授权董事会并由董事会授权董事长全 权办理本次发行公司债券相关事项的议案》等相关议案，本次发行公司债券事项 尚需提交公司股东大会审议。现将相关事项公告如下： 一、关于符合发行公司债券条件的说明 为促进公司稳健发展，加速推动科技创新，拓宽融资渠道，满足生产经营与 投资的资金需求，优化债务结构，经慎重考虑，公司拟通过在境内申请发行公司 债券的方式筹集资金。经逐项对照《中华人民共和国公司法》《中华人民共和国 证券法》《公司债券发行与交易管理办法》和《深圳证券交易所公司债券上市规 则》等法律、法规、部门规章、规范性文件和深圳证券交易所业务规则中关于公 开发行及非公开发行公司债券条件的规定，董事会、监事会认为 ...